Bio Green Med Stock Performance

BGMS Stock   0.98  0.01  1.01%   
The firm shows a Beta (market volatility) of 2.67, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Bio Green will likely underperform. At this point, Bio Green Med has a negative expected return of -0.0587%. Please make sure to confirm Bio Green's potential upside, as well as the relationship between the rate of daily change and period momentum indicator , to decide if Bio Green Med performance from the past will be repeated at some point in the near future.

Risk-Adjusted Performance

Weakest

 
Weak
 
Strong
Over the last 90 days Bio Green Med has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable primary indicators, Bio Green is not utilizing all of its potentials. The recent stock price uproar, may contribute to short-horizon losses for the private investors. ...more
1
Is Bio Green Med Solution Stock Built to Withstand More Downside - Trefis
12/03/2025
2
Acquisition by Cu Kiu of 200000 shares of Bio Green at 1.4 subject to Rule 16b-3
12/19/2025
3
Bio Green Med Solution, Inc. - 6 percent Convertible Preferred Stock Stock Quote - FinancialContent
01/02/2026
4
12 Health Care Stocks Moving In Fridays After-Market Session - Benzinga
02/06/2026

Bio Green Relative Risk vs. Return Landscape

If you would invest  121.00  in Bio Green Med on November 17, 2025 and sell it today you would lose (23.00) from holding Bio Green Med or give up 19.01% of portfolio value over 90 days. Bio Green Med is currently does not generate positive expected returns and assumes 7.8047% risk (volatility on return distribution) over the 90 days horizon. In different words, 70% of stocks are less volatile than Bio, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Bio Green is expected to under-perform the market. In addition to that, the company is 10.22 times more volatile than its market benchmark. It trades about -0.01 of its total potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.13 per unit of volatility.

Bio Green Target Price Odds to finish over Current Price

The tendency of Bio Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 0.98 90 days 0.98 
about 97.0
Based on a normal probability distribution, the odds of Bio Green to move above the current price in 90 days from now is about 97.0 (This Bio Green Med probability density function shows the probability of Bio Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the stock has the beta coefficient of 2.67 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Bio Green will likely underperform. Additionally Bio Green Med has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.
   Bio Green Price Density   
       Price  

Predictive Modules for Bio Green

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Bio Green Med. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
0.050.988.85
Details
Intrinsic
Valuation
LowRealHigh
0.050.978.84
Details

Bio Green Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Bio Green is not an exception. The market had few large corrections towards the Bio Green's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Bio Green Med, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Bio Green within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
-0.52
β
Beta against Dow Jones2.67
σ
Overall volatility
0.20
Ir
Information ratio -0.05

Bio Green Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Bio Green for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Bio Green Med can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Bio Green Med generated a negative expected return over the last 90 days
Bio Green Med has high historical volatility and very poor performance
Bio Green Med has some characteristics of a very speculative penny stock
Bio Green Med has high likelihood to experience some financial distress in the next 2 years
Bio Green Med was previously known as Cyclacel Pharmaceuticals and was traded on NASDAQ Exchange under the symbol CYCC.
The company reported the previous year's revenue of 43 K. Net Loss for the year was (11.21 M) with profit before overhead, payroll, taxes, and interest of 0.
Bio Green generates negative cash flow from operations
Bio Green Med has a poor financial position based on the latest SEC disclosures
Latest headline from news.google.com: 12 Health Care Stocks Moving In Fridays After-Market Session - Benzinga

Bio Green Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Bio Stock often depends not only on the future outlook of the current and potential Bio Green's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Bio Green's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding22.3 K
Cash And Short Term Investments3.1 M

Bio Green Fundamentals Growth

Bio Stock prices reflect investors' perceptions of the future prospects and financial health of Bio Green, and Bio Green fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Bio Stock performance.

About Bio Green Performance

Assessing Bio Green's fundamental ratios provides investors with valuable insights into Bio Green's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Bio Green is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Days Of Inventory On Hand 166.08  174.38 
Return On Tangible Assets(3.15)(2.99)
Return On Capital Employed 6.35  6.67 
Return On Assets(3.15)(2.99)
Return On Equity 5.93  6.23 

Things to note about Bio Green Med performance evaluation

Checking the ongoing alerts about Bio Green for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Bio Green Med help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Bio Green Med generated a negative expected return over the last 90 days
Bio Green Med has high historical volatility and very poor performance
Bio Green Med has some characteristics of a very speculative penny stock
Bio Green Med has high likelihood to experience some financial distress in the next 2 years
Bio Green Med was previously known as Cyclacel Pharmaceuticals and was traded on NASDAQ Exchange under the symbol CYCC.
The company reported the previous year's revenue of 43 K. Net Loss for the year was (11.21 M) with profit before overhead, payroll, taxes, and interest of 0.
Bio Green generates negative cash flow from operations
Bio Green Med has a poor financial position based on the latest SEC disclosures
Latest headline from news.google.com: 12 Health Care Stocks Moving In Fridays After-Market Session - Benzinga
Evaluating Bio Green's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Bio Green's stock performance include:
  • Analyzing Bio Green's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Bio Green's stock is overvalued or undervalued compared to its peers.
  • Examining Bio Green's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Bio Green's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Bio Green's management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Bio Green's stock. These opinions can provide insight into Bio Green's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Bio Green's stock performance is not an exact science, and many factors can impact Bio Green's stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Additional Tools for Bio Stock Analysis

When running Bio Green's price analysis, check to measure Bio Green's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio Green is operating at the current time. Most of Bio Green's value examination focuses on studying past and present price action to predict the probability of Bio Green's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio Green's price. Additionally, you may evaluate how the addition of Bio Green to your portfolios can decrease your overall portfolio volatility.